US · IRIX · MEDICAL - DEVICES
IRIDEX Corporation (IRIX) intrinsic value and stock valuation
$0.44as of 2026-11-21 · Mkt cap 14.61M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
IRIDEX Corporation DCF and intrinsic value
InvestorsCraft values IRIX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IRIX’s statements →
IRIDEX Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $52.7M | $48.7M | $51.9M | $57M | $53.9M |
| Operating income | -$-2.57M | -$-8.3M | -$-10.01M | -$-7.54M | -$-7.53M |
| Net income | -$-4.44M | -$-8.91M | -$-9.57M | -$-7.55M | -$-5.22M |
| EPSd | -$-258.29K | -$-541.97K | -$-593.3K | -$-473.65K | -$-338.52K |
| Operating cash flow | -$-2.12M | -$-7.29M | -$-6.75M | -$-9.52M | $8.22M |
| Capital expenditure | -$-140K | -$-10K | -$-110K | -$-290K | -$-210K |
| Free cash flow | -$-2.26M | -$-7.3M | -$-6.85M | -$-9.8M | $8M |
| Total assets | $29.2M | $29.1M | $34.4M | $42.3M | $48.7M |
| Total debt | $4.53M | $4.64M | $2.75M | $1.77M | $2.66M |
| Net debt | -$-1.5M | $2.26M | -$-4.29M | -$-12.15M | -$-21.2M |
| Total equity | $4.92M | $2.1M | $9.52M | $17.2M | $23.3M |
| Cash and short-term investments | $6.03M | $2.39M | $7.03M | $13.9M | $23.9M |
Income statement
| 2026 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $52.7M | $48.7M | $51.9M | $57M | $53.9M |
| Cost of revenue | $33.4M | $29.2M | $30.1M | $31.6M | $31.1M |
| Gross profit | $19.3M | $19.5M | $21.8M | $25.4M | $22.8M |
| Research and development expenses | $3.67M | $5.45M | $6.83M | $7.17M | $6.87M |
| Selling, general and administrative expenses | $18.1M | $22.4M | $25M | $25.7M | $23.5M |
| Other expenses | $80K | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $21.9M | $27.8M | $31.8M | $32.9M | $30.4M |
| Cost and expenses | $55.3M | $57M | $61.9M | $64.5M | $61.4M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $1.55M | $1.42M | $2.03M | $1.38M | $800K |
| Ebitda | -$-2.83M | -$-7.42M | -$-7.45M | -$-6.1M | -$-4.38M |
| Operating income | -$-2.57M | -$-8.3M | -$-10.01M | -$-7.54M | -$-7.53M |
| Total other income/expenses, net | -$-1.81M | -$-540K | $530K | $60K | $2.35M |
| Income before tax | -$-4.38M | -$-8.84M | -$-9.48M | -$-7.48M | -$-5.18M |
| Income tax expense | $60K | $70K | $90K | $70K | $40K |
| Net income | -$-4.44M | -$-8.91M | -$-9.57M | -$-7.55M | -$-5.22M |
| Weighted average shares outstanding | $17.2M | $16.4M | $16.1M | $15.9M | $15.4M |
| Weighted average diluted shares outstanding | $17.2M | $16.4M | $16.1M | $15.9M | $15.4M |
Balance sheet
| 2026 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $6.03M | $2.39M | $7.03M | $13.9M | $23.9M |
| Net receivables | $9.54M | $8.39M | $9.65M | $9.77M | $9.72M |
| Inventory | $7.88M | $10.8M | $9.91M | $10.6M | $7.61M |
| Total current assets | $25.3M | $23.6M | $27.5M | $35.8M | $42.3M |
| Property, plant and equipment, net | $830K | $1.91M | $2.98M | $2.13M | $2.99M |
| Goodwill and intangible assets | $1.95M | $2.27M | $2.61M | $2.94M | $3.17M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $3.9M | $5.57M | $6.99M | $6.52M | $6.43M |
| Total assets | $29.2M | $29.1M | $34.4M | $42.3M | $48.7M |
| Accounts payable | $5.38M | $6.99M | $4.5M | $3.86M | $2.77M |
| Short-term debt | $700K | $2.83M | $990K | $1.04M | $930K |
| Deferred revenue | $3.68M | $3.49M | $3.33M | $3.38M | $3.45M |
| Total current liabilities | $13.2M | $16.6M | $13M | $12.5M | $12.7M |
| Long-term debt | $3.83M | $1.81M | $1.75M | $730K | $1.73M |
| Deferred revenue, non-current | $6.8M | $8.35M | $10M | $11.7M | $10.9M |
| Total non-current liabilities | $11M | $10.5M | $11.9M | $12.6M | $12.7M |
| Capital lease obligations | $800K | $1.91M | $2.75M | $1.77M | $2.66M |
| Total liabilities | $24.2M | $27M | $24.9M | $25.1M | $25.4M |
| Common stock | $170K | $170K | $170K | $170K | $170K |
| Retained earnings | -$-92.45M | -$-88.01M | -$-79.04M | -$-69.72M | -$-62.17M |
| Accumulated other comprehensive income (loss) | -$-10K | $50K | -$-50K | -$-20K | $40K |
| Total equity | $4.92M | $2.1M | $9.52M | $17.2M | $23.3M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $4.53M | $4.64M | $2.75M | $1.77M | $2.66M |
| Net debt | -$-1.5M | $2.26M | -$-4.29M | -$-12.15M | -$-21.2M |
Cash flow statement
| 2026 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-4.44M | -$-8.91M | -$-9.57M | -$-7.55M | -$-5.22M |
| Depreciation and amortization | $1.55M | $1.42M | $2.03M | $1.38M | $1.71M |
| Stock-based compensation | $780K | $1.24M | $1.65M | $1.62M | $1.63M |
| Change in working capital | -$-2.38M | -$-1.37M | -$-860K | -$-5.16M | $12.6M |
| Accounts receivable | -$-1.15M | $1.26M | $360K | -$-240K | -$-2.47M |
| Inventory | $2.12M | -$-910K | $640K | -$-3.02M | $270K |
| Accounts payable | -$-1.95M | $2.49M | $640K | $1.09M | $1.62M |
| Net cash provided by operating activities | -$-2.12M | -$-7.29M | -$-6.75M | -$-9.52M | $8.22M |
| Investments in property, plant and equipment | -$-140K | -$-10K | -$-110K | -$-290K | -$-210K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | -$-5.34M |
| Net cash used for investing activities | -$-140K | -$-10K | -$-110K | -$-290K | -$-5.56M |
| Common stock issued | $6M | $3.37M | $80K | $20K | $9.88M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $5.96M | $2.6M | -$-10K | -$-70K | $9.47M |
| Net change in cash | $3.64M | -$-4.65M | -$-6.89M | -$-9.93M | $12.2M |
| Cash at end of period | $6.03M | $2.39M | $7.03M | $13.9M | $23.9M |
| Operating cash flow | -$-2.12M | -$-7.29M | -$-6.75M | -$-9.52M | $8.22M |
| Capital expenditure | -$-140K | -$-10K | -$-110K | -$-290K | -$-210K |
| Free cash flow | -$-2.26M | -$-7.3M | -$-6.85M | -$-9.8M | $8M |
Line items
Line items
Line items
About IRIDEX Corporation
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
- CEO
- Patrick Mercer
- Employees
- 93
- Beta
- 0.64
Explore
Frequently asked questions
What is the intrinsic value of IRIDEX Corporation (IRIX)?
InvestorsCraft does not currently publish an intrinsic value for IRIX. How the IC value is calculated.
Is IRIX undervalued?
InvestorsCraft does not publish an undervaluation signal for IRIX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.